126 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
13 Aug 21
51-102F3 Material Change Report
12:00am
NEWS RELEASE
RepliCel Closes Second Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Largest Scheduled Share … by the Company.
MainPointe’s investment commitment, totaling CAD $2.7M, will be made over a series of tranches involving the purchase of four million
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
13 Aug 21
RepliCel CEO Provides Corporate Update
12:00am
NEWS RELEASE
RepliCel Closes First Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Initial Share Purchase per … investment commitment, totaling CAD $2.7M, will be made over a series of four tranches involving the purchase of four million common shares at CAD $0.675
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
6 Nov 18
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
11:03am
and fulfils commitment to promote female leadership in biotech
VANCOUVER, Nov. 06, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP … is also an example of RepliCel's commitment to fulfill its part in the industry's promise to promote female leadership in the industry."
Dr. Goessens
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
of Simon Ma, our long tenured Chief Financial Officer. “Simon Ma has been a valuable member of the team for many years, Simon’s deep commitment … to the Company was always evident. We spent many late nights engaged on projects together. Simon’s commitment was unwavering, and he left an enduring impact
6-K
EX-99.3
imx2pv
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
xswyas6e
30 Aug 06
Current report (foreign)
12:00am
6-K
EX-99.6
5uoxs
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.5
ycxjsb8qfx8h9y 4k
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
amsfpo1kufq
30 Nov 06
Current report (foreign)
12:00am
6-K
EX-99.2
ds95h81uk 74mv13u
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
aypwz
16 Feb 11
Current report (foreign)
12:00am
6-K
EX-99.3
f75qsncg6
21 Dec 21
51-102F3 Material Change Report
5:28pm
6-K
EX-99.1
ixqmw8tl32cg 2rzyp7
29 Aug 19
RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector
11:47am
6-K
EX-99.1
dnn9u1
11 Oct 18
RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
11:45am
6-K
EX-99.1
b3ctyawz2pom86u
20 Apr 16
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
12:00am
6-K
EX-99.1
i2t092
24 Sep 18
RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
10:48am